Postmenopausal vaginal atrophy therapeutics pipeline assessment and market forecasts to 2019

Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and MarketForecasts to 2019Company announces 10% Discount on this report.Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019SummaryCompany, the industry analysis specialist, has released its new report, “Postmenopausal Vaginal AtrophyTherapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source ofinformation and analysis on the global Postmenopausal Vaginal Atrophy Therapeutics market. The reportidentifies the key trends shaping and driving the global Postmenopausal Vaginal Atrophy Therapeutics market.The report also provides insights on the prevalent competitive landscape and the emerging players expected tosignificantly alter the market positioning of the current market leaders. Most importantly, the report providesvaluable insights on the pipeline products within the global Postmenopausal Vaginal Atrophy Therapeuticssector. This report is built using data and information sourced from proprietary databases, primary andsecondary research and in-house analysis by Company team of industry experts.ScopeThe report provides information on the key drivers and challenges of the Postmenopausal Vaginal AtrophyTherapeutics market. Its scope includes -- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Postmenopausal VaginalAtrophy Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.- Pipeline analysis data providing a split across the different phases, mechanisms of action being developedand emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.- Analysis of the current and future competition in the seven key countries Postmenopausal Vaginal AtrophyTherapeutics market.- Insightful review of the key industry drivers, restraints and challenges. Each trend is independentlyresearched to provide a qualitative analysis of its implications.- Key topics covered include strategic competitor assessment, market characterization, unmet needs and theimplications for the Postmenopausal Vaginal Atrophy Therapeutics market.- Analysis of key recent licensing and partnership agreements in Postmenopausal Vaginal Atrophy TherapeuticsmarketReasons to buyThe report will enhance your decision making capability. It will allow you to -- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products andtechnologies and by identifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global PostmenopausalVaginal Atrophy Therapeutics market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments andcompanies likely to impact the global Postmenopausal Vaginal Atrophy Therapeutics market in future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and byanalyzing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies togain a competitive advantage.- Organize your sales and marketing efforts by identifying the market categories and segments that presentmaximum opportunities for consolidations, investments and strategic partnerships.- What the next big thing in the global Postmenopausal Vaginal Atrophy Therapeutics market landscape? –Identify, understand and capitalize.

Table of Contents :1.1 List of Tables 51.2 List of Figures 62 Postmenopausal Vaginal Atrophy Therapeutics - Introduction 72.1 Disease Overview 72.2 Epidemiology 72.3 Etiology 72.4 Pathophysiology 82.5 Signs and Symptoms 82.6 Diagnosis 82.6.1 Laboratory Diagnosis Tests 82.7 Treatment and Management Options 92.7.1 Vaginal Cream 92.7.2 Estradiol Ring 92.7.3 Vaginal Tablet 92.8 GlobalData Pipeline Report Guidance 103 Postmenopausal Vaginal Atrophy Therapeutics - Market Characterization 113.1 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Global 113.2 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Global 133.3 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - The US 143.4 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - The US 153.5 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - France 163.6 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - France 173.7 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Germany 183.8 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Germany 193.9 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Italy 203.10 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Italy 213.11 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Spain 223.12 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Spain 233.13 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - The UK 243.14 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - The UK 253.15 Postmenopausal Vaginal Atrophy Therapeutics Market Size (2006-2011) - Japan 263.16 Postmenopausal Vaginal Atrophy Therapeutics Market Forecast (2011-2019) - Japan 273.17 Drivers and Barriers for the Postmenopausal Vaginal Atrophy Therapeutics Market 283.17.1 Drivers for the Postmenopausal Vaginal Atrophy Therapeutics Market 283.17.2 Barriers to the Postmenopausal Vaginal Atrophy Therapeutics Market 283.18 Opportunity and Unmet Need Analysis 293.19 Key Takeaway 294 Postmenopausal Vaginal Atrophy Therapeutics - Competitive Assessment 304.1 Overview 304.2 Strategic Competitor Assessment 304.3 Product Profiles for the Major Marketed Products in the Postmenopausal Vaginal Atrophy TherapeuticsMarket 314.3.1 Vaginal Cream 314.3.2 Estrace 314.3.3 Premarin 314.3.4 Vaginal Ring 324.3.5 Estring 324.3.6 Femring 334.3.7 Vaginal Tablet 344.3.8 Vagifem 344.4 Key Takeaway 355 Postmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment 365.1 Overview 365.2 Strategic Pipeline Assessment 365.3 Postmenopausal Vaginal Atrophy Therapeutics Pipeline - Pipeline by Phase of Development 365.3.1 Postmenopausal Vaginal Atrophy Therapeutics - Phase III Pipeline 365.3.2 Postmenopausal Vaginal Atrophy Therapeutics - Phase II Pipeline 375.3.3 Postmenopausal Vaginal Atrophy Therapeutics - Phase I Pipeline 375.3.4 Postmenopausal Vaginal Atrophy Therapeutics - Pre-Clinical Pipeline 375.3.5 Postmenopausal Vaginal Atrophy Therapeutics - Unknown Phase 375.3.6 Technology Trends Analytic Framework 38

5.4 Postmenopausal Vaginal Atrophy Therapeutics Market - Pipeline by Mechanism of Action 405.5 Postmenopausal Vaginal Atrophy Therapeutics - Promising Drugs under Clinical Development 405.6 Molecule Profile for Promising Drugs under Clinical Development 415.6.1 Ophena (ospemifene) 415.6.2 Vaginorm (dehydroepiandrosterone) 415.7 Key Takeaway 426 Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials Mapping 436.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 436.2 Clinical Trials by Phase 446.3 Clinical Trials by Trial Status 456.4 Prominent Sponsors 466.5 Clinical Trials by Overall Sponsors 476.6 Top Companies Participating in Postmenopausal Vaginal Atrophy Therapeutics Clinical Trials 487 Postmenopausal Vaginal Atrophy Therapeutics - Strategic Assessment 497.1 Key Events Impacting the Future Market 497.2 Postmenopausal Vaginal Atrophy Therapeutics - Implications for Future Market Competition 508 Postmenopausal Vaginal Atrophy Therapeutics - Future Players 518.1 Introduction 518.2 Company Profiles 518.2.1 Bionovo, Inc. (Bionovo) 518.2.2 QuatRx Pharmaceutical Company 538.2.3 Shionogi & Co. 538.2.4 EndoCeutics, Inc 548.2.5 Bayer AG 548.2.6 Other Companies in Postmenopausal Vaginal Atrophy Therapeutics Market 559 Postmenopausal Vaginal Atrophy Therapeutics - Appendix 569.1 Market Definitions 569.2 Acronyms 569.3 Methodology 569.3.1 Coverage 579.3.2 Secondary Research 579.3.3 Forecasting 579.3.4 Primary Research 609.3.5 Expert Panel Validation 609.4 Contact Us 609.5 Disclaimer 609.6 Bibliography 611.1 List of TablesTable 1: Postmenopausal Vaginal Atrophy Prevalence in The US, EU5 and Japan 7Table 2: Treatment Options for Postmenopausal Vaginal Atrophy 9Table 3: Postmenopausal Vaginal Atrophy Therapeutics Market, Global, Revenue ($m), 2006-2011 12Table 4: Postmenopausal Vaginal Atrophy Therapeutics Market, Global, Forecast ($m), 2011-2019 13Table 5: Postmenopausal Vaginal Atrophy Therapeutics Market, The US, Revenue ($m), 2006-2011 14Table 6: Postmenopausal Vaginal Atrophy Therapeutics Market, The US, Forecast ($m), 2011-2019 15Table 7: Postmenopausal Vaginal Atrophy Therapeutics Market, France, Revenue ($m), 2006-2011 16Table 8: Postmenopausal Vaginal Atrophy Therapeutics Market, France, Forecast ($m), 2011-2019 17Table 9: Postmenopausal Vaginal Atrophy Therapeutics Market, Germany, Revenue ($m), 2006-2011 18Table 10: Postmenopausal Vaginal Atrophy Therapeutics Market, Germany, Forecast ($m), 2010-2019 19Table 11: Postmenopausal Vaginal Atrophy Therapeutics Market, Italy, Revenue ($m), 2006-2011 20Table 12: Postmenopausal Vaginal Atrophy Therapeutics Market, Italy, Forecast ($m), 2011-2019 21Table 13: Postmenopausal Vaginal Atrophy Therapeutics Market, Spain, Revenue ($m), 2006-2011 22Table 14: Postmenopausal Vaginal Atrophy Therapeutics Market, Spain, Forecast ($m), 2011-2019 23Table 15: Postmenopausal Vaginal Atrophy Therapeutics Market, The UK, Revenue ($m), 2006-2011 24Table 16: Postmenopausal Vaginal Atrophy Therapeutics Market, The UK, Forecast ($m), 2011-2019 25Table 17: Postmenopausal Vaginal Atrophy Therapeutics Market, Japan, Revenue ($m), 2006-2011 26Table 18: Postmenopausal Vaginal Atrophy Therapeutics Market, Japan, Forecast ($m), 2011-2019 27Table 19: Postmenopausal Vaginal Atrophy Therapeutics - Phase III Pipeline, 2011 36Table 20: Postmenopausal Vaginal Atrophy Therapeutics - Phase II Pipeline, 2011 37Table 21: Postmenopausal Vaginal Atrophy Therapeutics - Phase I Pipeline, 2011 37Table 22: Postmenopausal Vaginal Atrophy Therapeutics - Pre-Clinical Pipeline, 2011 37Table 23: Postmenopausal Vaginal Atrophy Therapeutics - Unknown Phase, 2011 37

Table 24: Postmenopausal Vaginal Atrophy Therapeutics - Most Promising Drugs Under Clinical Development,2011 40Table 25: Postmenopausal Vaginal Atrophy Therapeutics Market - Clinical Trials by Country, 2011 43Table 26: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Phase, 2011 44Table 27: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Status, 2011 45Table 28: Postmenopausal Vaginal Atrophy Therapeutics - Prominent Sponsors, 2011 46Table 29: Postmenopausal Vaginal Atrophy Therapeutics - Overall Sponsors, 2011 47Table 30: Postmenopausal Vaginal Atrophy Therapeutics - Top Companies Participating in Therapeutics ClinicalTrials, 2011 48Table 31 Bionovo Inc., Women’s Healthcare Pipeline, 2011 52Table 32: QuatRx Pharmaceuticals Company, Women’s Healthcare Pipeline, 2011 53Table 33: Shionogi Pharmaceuticals - Women’s Healthcare Pipeline, 2011 53Table 34: EndoCeutics - Women’s Healthcare Pipeline, 2011 54Table 35 Bayer AG - Women’s Healthcare Pipeline, 2011 55Table 36: Postmenopausal Vaginal Atrophy Therapeutics Market - Future Players 551.2 List of FiguresFigure 1: Postmenopausal Vaginal Atrophy Therapeutics Market, Global, Revenue ($m), 2006-2011 11Figure 2: Postmenopausal Vaginal Atrophy Therapeutics Market, Global, Forecast ($m), 2011-2019 13Figure 3: Postmenopausal Vaginal Atrophy Therapeutics Market, The US, Revenue ($m), 2006-2011 14Figure 4: Postmenopausal Vaginal Atrophy Therapeutics Market, The US, Forecast ($m), 2011-2019 15Figure 5: Postmenopausal Vaginal Atrophy Therapeutics Market, France, Revenue ($m), 2006-2011 16Figure 6: Postmenopausal Vaginal Atrophy Therapeutics Market, France, Forecast ($m), 2011-2019 17Figure 7: Postmenopausal Vaginal Atrophy Therapeutics Market, Germany, Revenue ($m), 2006-2011 18Figure 8: Postmenopausal Vaginal Atrophy Therapeutics Market, Germany, Forecast ($m), 2011-2019 19Figure 9: Postmenopausal Vaginal Atrophy Therapeutics Market, Italy, Revenue ($m), 2006-2011 20Figure 10: Postmenopausal Vaginal Atrophy Therapeutics Market, Italy, Forecast ($m), 2011-2019 21Figure 11: Postmenopausal Vaginal Atrophy Therapeutics Market, Spain, Revenue ($m), 2006-2011 22Figure 12: Postmenopausal Vaginal Atrophy Therapeutics Market, Spain, Forecast ($m), 2011-2019 23Figure 13: Postmenopausal Vaginal Atrophy Therapeutics Market, The UK, Revenue ($m), 2006-2011 24Figure 14: Postmenopausal Vaginal Atrophy Therapeutics Market, The UK, Forecast ($m), 2011-2019 25Figure 15: Postmenopausal Vaginal Atrophy Therapeutics Market, Japan, Revenue ($m), 2006-2011 26Figure 16: Postmenopausal Vaginal Atrophy Therapeutics Market, Japan, Forecast ($m), 2011-2019 27Figure 17: Opportunity and Unmet Need in the Postmenopausal Vaginal Atrophy Therapeutics Market, 2011 29Figure 18: Postmenopausal Vaginal Atrophy Therapeutics - Strategic Competitor Assessment, 2011 30Figure 19: Postmenopausal Vaginal Atrophy Therapeutics - Pipeline by Phase of Development, 2011 36Figure 20: Postmenopausal Vaginal Atrophy Therapeutics - Technology Trends Analytics Framework, 2011 38Figure 21: Postmenopausal Vaginal Atrophy Therapeutics - Technology Trends Analytics Framework -Description, 2011 39Figure 22: Postmenopausal Vaginal Atrophy Therapeutics - Pipeline by Mechanism of Action, 2011 40Figure 23: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Country, 2011 43Figure 24: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Phase, 2011 44Figure 25: Postmenopausal Vaginal Atrophy Therapeutics - Clinical Trials by Status, 2011 45Figure 26: Postmenopausal Vaginal Atrophy Therapeutics - Prominent Sponsors, 2011 46Figure 27: Postmenopausal Vaginal Atrophy Therapeutics - Overall Sponsors, 2011 47Figure 28: Postmenopausal Vaginal Atrophy Therapeutics - Top Companies Participating in Therapeutics ClinicalTrials, 2011 48Figure 29: Postmenopausal Vaginal Atrophy Therapeutics Market - Drivers and Barriers, 2011 49Figure 30: Implications for Future Market Competition in the Postmenopausal Vaginal Atrophy Market, 2011 50Figure 31: Postmenopausal Vaginal Atrophy Therapeutics Market - Pipeline by Company, 2011 51Figure 32: GlobalData Market Forecasting Model 59Company Mentioned:Bionovo, Inc. (Bionovo)QuatRx Pharmaceutical CompanyShionogi & Co.EndoCeutics, IncBayer AG

For more information, please visit:http://www.aarkstore.com/reports/Postmenopausal-Vaginal-Atrophy-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2019-198835.htmlOr email us at contact@aarkstore.com or call +918149852585July12 Best Sellers on Discount this Aug12Medical EquipmentCardiac Rhythm Management Devices Market to 2017 - Technological Innovations, RegulatoryApprovals and Increasing Disease Prevalence Present Growth OpportunitiesCardiac Assist Device Market to 2017 – Increasing Uptake of Ventricular Assist Devices and TotalArtificial Heart to Drive GrowthSpinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and MarketForecasts to 2017Extremities (Shoulder and Small Joint Implants) - Global Pipeline Analysis, Competitive Landscapeand Market Forecasts to 2017External Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to2017Pharmaceuticals and HealthcarePostmenopausal Vaginal Atrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2019Acne Therapeutics - Pipeline Assessment and Market Forecasts to 2018Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars toDrive RevenuesRx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management andSmoking Cessation, but Encouraging the Uptake of Self-Medication Remains a ChallengeAntifungals Market to 2017 - Generic Erosion of Major Polyenes, Azoles, Allylamines andEchinocandins to Slow Value GrowthEnergyOil Sands Industry in Canada, 2011 – Market Analysis, Competitive Landscape and ProductionForecasts to 2015Global Gas Shales Development, 2011 - North America Sets The Momentum For Shale GasDevelopments WorldwideFloating Production Storage and Offloading (FPSO)and Floating Storage and Offloading (FSO)Industry to 2016 - Rise of Deepwater Hydrocarbon Production Leading to Industry GrowthRefining Industry to 2016 - Increasing Margins and Rise in Product Demand Set to Drive CapacityExpansions in Asia and Middle EastOil and Gas Enhanced Production Services Industry to 2015 - Enhanced Oil Recovery Proving to bea Key Solution for Tapping Unconventional Reservoirs and Depleting Oil FieldsLubricant Industry to 2015 - Surge in the Automotive Market in Emerging Economies DrivingDemandPower & Alternative EnrergyHydro Power Market to 2020 - Energy Management Strategies and Green Funds to Drive EmergingMarkets in Latin America and AfricaWind Energy Maintenance Market to 2020-Growth Driven by Increasing Competition betweenOEMs and ISPs in the Post-Warranty Maintenance SegmentThermal Power Maintenance Market to 2020 - Rising Electricity Demand and New Installations

Stimulate Asia Pacific and Middle East MarketsVessels, Cables and Foundations in the Offshore Wind market - Global Market Size, Cost Analysis,Market Share and Demand-Supply Scenario to 2020Wind Turbine Market, 2012 Update - Global Installations, Market Share and Key Country AnalysisChemicalsPaint Additives Market to 2016 - Rheology Modifiers and Biocides to Drive the MarketPetrochemical Industry in the Middle East - Low Cost Feedstock Providing Competitive AdvantagePetroleum Coke Industry to 2015 - Strong Demand Growth Driven by Increased Focus on FuelDiversificationCleanTechnologyVisible Light Communication (VLC) - A Potential Solution to the Global Wireless Spectrum ShortageE-Waste Management Market to 2020 - Emerging Economies Poised to Capitalize on the E-wasteRecovery and Recycling MarketGreen Aviation Market to 2020 - Stringent Regulations to Drive Investment in Green TechnologiesClean Coal Market to 2020 - Adoption of advanced technologies like IGCC will spur due to rise inconsumer demand and stringent environmental regulationsAarkstore EnterpriseTel : +912227453309Mobile No: +919272852585Email : contact@aarkstore.comWebsite : http://www.aarkstore.comhttp://www.facebook.com/aarkstoreenterprisehttp://in.linkedin.com/in/aarkstoreBlog: http://blogs.aarkstore.com/Follow us on twitter: http://twitter.com/aarkstoredotcom

Postmenopausal vaginal atrophy therapeutics pipeline assessment and market forecasts to 2019

by Aarkstore Enterprise on Aug 07, 2012

Accessibility

Categories

Upload Details

Usage Rights

Statistics

Postmenopausal vaginal atrophy therapeutics pipeline assessment and market forecasts to 2019 Document Transcript